{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:50:07Z","timestamp":1790700607671,"version":"4.1.0"},"reference-count":283,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Graves\u2019 ophthalmopathy is an debilitating disease impairing the quality of life of affected individuals. Despite recent progress in the understanding of its pathogenesis, treatment is often not satisfactory. In mild cases, local therapeutic measures (artificial tears and ointments, sunglasses, nocturnal taping of the eyes, prisms) can control symptoms and signs. In severe forms of the disease (3\u20135%), aggressive measures are required. If the disease is active, high-dose glucocorticoids and\/or orbital radiotherapy, or orbital decompression represent the mainstay of treatment. If the disease is severe but inactive, orbital decompression is preferred. Novel treatments such as somatostatin analogs or intravenous immunoglobulins are under evaluation. Rehabilitative (extraocular muscle or eyelid) surgery is often needed after treatment and inactivation of eye disease. Correction of both hyper- and hypothyroidism is crucial for the ophthalmopathy. Antithyroid drugs and thyroidectomy do not influence the course of the ophthalmopathy, whereas radioiodine treatment may cause the progression of preexisting ophthalmopathy, especially in smokers. The exacerbation, however, is prevented by glucocorticoids. In addition, thyroid ablation may prove beneficial for the ophthalmopathy in view of the pathogenetic model relating eye disease to autoimmune reactions directed against antigens shared by the thyroid and the orbit.<\/jats:p>","DOI":"10.1210\/edrv.21.2.0393","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T13:26:43Z","timestamp":1389187603000},"page":"168-199","source":"Crossref","is-referenced-by-count":64,"title":["Management of Graves\u2019 Ophthalmopathy: Reality and Perspectives*"],"prefix":"10.1210","volume":"21","author":[{"given":"Luigi","family":"Bartalena","sequence":"first","affiliation":[{"name":"Dipartimento di Endocrinologia e Metabolismo, Ortopedia e Traumatologia, Medicina del Lavoro, University of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Pinchera","sequence":"first","affiliation":[{"name":"Dipartimento di Endocrinologia e Metabolismo, Ortopedia e Traumatologia, Medicina del Lavoro, University of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Marcocci","sequence":"first","affiliation":[{"name":"Dipartimento di Endocrinologia e Metabolismo, Ortopedia e Traumatologia, Medicina del Lavoro, University of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2016,11,7]]},"reference":[{"key":"2020071612053021500_R1","first-page":"747","article-title":"Graves\u2019 ophthalmopathy: current concepts regarding pathogenesis and management.","volume":"14","author":"Burch","year":"1993","journal-title":"Endocr Rev"},{"key":"2020071612053021500_R2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/thy.1997.7.885","article-title":"Quality of life in patients with Graves\u2019 ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study Instrument.","volume":"7","author":"Gerding","year":"1997","journal-title":"Thyroid"},{"key":"2020071612053021500_R3","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199311113292007","article-title":"Pathogenesis of Graves\u2019 ophthalmopathy.","volume":"329","author":"Bahn","year":"1993","journal-title":"N Engl J Med"},{"key":"2020071612053021500_R4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/thy.1994.4.379","article-title":"Pathogenesis of Graves\u2019 ophthalmopathy.","volume":"4","author":"Gorman","year":"1994","journal-title":"Thyroid"},{"key":"2020071612053021500_R5","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1530\/eje.0.1320532","article-title":"Pathogenesis of Graves\u2019 ophthalmopathy: recent controversies and progress.","volume":"132","author":"Heufelder","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"2020071612053021500_R6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0950-351X(97)80738-0","article-title":"Treating severe Graves\u2019 ophthalmopathy.","volume":"11","author":"Bartalena","year":"1997","journal-title":"Bailliere\u2019s Clin Endocrinol Metab"},{"key":"2020071612053021500_R7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/acta.0.1200473","article-title":"Studies on the occurrence of ophthalmopathy in Graves\u2019 disease.","volume":"120","author":"Marcocci","year":"1989","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071612053021500_R8","first-page":"222","article-title":"Immunohistochemical analysis of the retrobulbar tissues in Graves\u2019 ophthalmopathy.","volume":"75","author":"Weetman","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"2020071612053021500_R9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1530\/eje.0.1320264","article-title":"Seeing T cells behind the eye.","volume":"132","author":"Davies","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"2020071612053021500_R10","first-page":"3045","article-title":"Orbital tissue-derived T lymphocytes from patients with Graves\u2019 ophthalmopathy recognize autologous orbital antigens.","volume":"81","author":"Otto","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R11","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.1365-2249.1997.4491347.x","article-title":"Analysis of extraocular muscle-infiltrating T cells in thyroid-associated ophthalmopathy (TAO).","volume":"109","author":"Pappa","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"2020071612053021500_R12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1530\/eje.0.1340051","article-title":"Characterization of adhesion receptors on cultured microvascular endothelial cells derived from the retroorbital connective tissue of patients with Graves\u2019 ophthalmopathy.","volume":"134","author":"Heufelder","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"2020071612053021500_R13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1046\/j.1365-2249.1997.3621258.x","article-title":"Adhesion molecules expression in vivo on extraocular muscles (EOM) in thyroid-associated ophthalmopathy (TAO).","volume":"108","author":"Pappa","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"2020071612053021500_R14","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1530\/eje.0.1320266","article-title":"Analysis of retroorbital T cell antigen receptor variable region gene usage in patients with Graves\u2019 ophthalmopathy.","volume":"132","author":"Heufelder","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"2020071612053021500_R15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1089\/thy.1998.8.419","article-title":"T-cell restriction in thyroid eye disease.","volume":"8","author":"Heufelder","year":"1998","journal-title":"Thyroid"},{"key":"2020071612053021500_R16","first-page":"1","article-title":"Graves\u2019 ophthalmopathy.","volume":"3","author":"Wiersinga","year":"1997","journal-title":"Thyroid International"},{"key":"2020071612053021500_R17","first-page":"1120","article-title":"Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves\u2019 ophthalmopathy.","volume":"77","author":"De Carli D\u2019Elios","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R18","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1172\/JCI117289","article-title":"Retrobulbar T cells from patients with Graves\u2019 ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts.","volume":"3","author":"Grubeck-Loebenstein","year":"1994","journal-title":"J Clin Invest"},{"key":"2020071612053021500_R19","first-page":"1070","article-title":"Cell-mediated or humoral immunity in Graves\u2019 ophthalmopathy? Profiles of T-cell cytokines amplified by polymerase chain reaction from orbital tissue.","volume":"78","author":"McLachlan","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2249.1998.00613.x","article-title":"Analysis of orbital T cells in thyroid-associated ophthalmopathy.","volume":"112","author":"Forster","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"2020071612053021500_R21","first-page":"446","article-title":"Cytokine antagonists: new ideas for the management of Graves\u2019 ophthalmopathy.","volume":"81","author":"Bartalena","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R22","first-page":"287","article-title":"Graves\u2019 ophthalmopathy: the role of cytokines in pathogenesis. In: Gass GH, Kaplan HM (eds) Handbook of Endocrinology, ed 2.","volume":"1","author":"Bahn","year":"1996","journal-title":"CRC Press Inc, Boca Raton, FL, vol"},{"key":"2020071612053021500_R23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1210\/jcem-73-2-307","article-title":"Increased induction of HLA-DR by interferon-\u03b3 in cultured retroocular fibroblasts derived from patients with Graves\u2019 ophthalmopathy and pretibial myxedema.","volume":"73","author":"Heufelder","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2362.1993.tb00712.x","article-title":"Modulation of intercellular adhesion molecule-1 (ICAM-1) by cytokines and Graves\u2019 IgGs in cultured Graves\u2019 retroocular fibroblasts.","volume":"23","author":"Heufelder","year":"1992","journal-title":"Eur J Clin Invest"},{"key":"2020071612053021500_R25","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1210\/jcem-72-5-1169","article-title":"Stimulation of glycosaminoglycan accumulation by interferon \u03b3 in cultured retro-ocular fibroblasts.","volume":"72","author":"Smith","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R26","first-page":"2037","article-title":"Stimulation of glycosaminoglycan production in cultured human retroocular fibroblasts.","volume":"33","author":"Korducki","year":"1992","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2020071612053021500_R27","first-page":"120","article-title":"Modulation of Graves\u2019 orbital fibroblast proliferation by cytokines and glucocorticoid receptor agonists.","volume":"35","author":"Heufelder","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2020071612053021500_R28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000237259","article-title":"Retrobulbar fibroblasts from patients with Graves\u2019 ophthalmopathy induce downregulation of APO-1 in T lymphocytes and protect T cells from apoptosis during coculture.","volume":"109","author":"Mohacsi","year":"1996","journal-title":"Int Arch Allergy Immunol"},{"key":"2020071612053021500_R29","first-page":"3428","article-title":"Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture.","volume":"81","author":"Sorisky","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/01676839609150229","article-title":"A possible role for the thyrotropin receptor in thyroid-associated ophthalmopathy.","volume":"15","author":"Bahn","year":"1996","journal-title":"Orbit"},{"key":"2020071612053021500_R31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0950-351X(97)80723-9","article-title":"Retro-orbital autoimmunity.","volume":"11","author":"Heufelder","year":"1997","journal-title":"Bailliere\u2019s Clin Endocrinol Metab"},{"key":"2020071612053021500_R32","first-page":"595","author":"McGregor","year":"1998"},{"key":"2020071612053021500_R33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0140-6736(93)91475-2","article-title":"Expression of thyrotropin-receptor mRNA in healthy and Graves\u2019 disease retro-orbital tissue.","volume":"342","author":"Feliciello","year":"1993","journal-title":"Lancet"},{"key":"2020071612053021500_R34","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1006\/bbrc.1993.1116","article-title":"Thyrotropin receptor in non-thyroid tissue.","volume":"190","author":"Endo","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071612053021500_R35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/thy.1993.3.297","article-title":"Detection of TSH receptor mRNA in cultured fibroblasts from patients with Graves\u2019 ophthalmopathy and pretibial dermopathy.","volume":"3","author":"Heufelder","year":"1993","journal-title":"Thyroid"},{"key":"2020071612053021500_R36","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF03347732","article-title":"TSH receptor gene expression in retroocular fibroblasts.","volume":"17","author":"Mengistu","year":"1994","journal-title":"J Endocrinol Invest"},{"key":"2020071612053021500_R37","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1074\/jbc.270.18.10833","article-title":"Cloning and functional expression of a thyrotropin receptor cDNA from rat cells.","volume":"270","author":"Endo","year":"1995","journal-title":"J Biol Chem"},{"key":"2020071612053021500_R38","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2265.1995.tb02681.x","article-title":"Current evidence for and against the TSH receptor being the common antigen in Graves\u2019 disease and thyroid associated ophthalmopathy.","volume":"42","author":"Paschke","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R39","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/0006-291X(92)91360-3","article-title":"Molecular cloning and sequencing of an alternatively spliced form of the human thyrotropin receptor transcript.","volume":"188","author":"Takeshita","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071612053021500_R40","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/0006-291X(92)91315-H","article-title":"Cloning and sequencing of a 1.3 kB variant of the human thyrotropin receptor mRNA lacking the transmembrane domain.","volume":"187","author":"Graves","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071612053021500_R41","first-page":"1234","article-title":"Presence of non-functional thyrotropin receptor variant transcripts in retroocular and other tissues.","volume":"79","author":"Paschke","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF02994449","article-title":"Novel splicing variants of the human thyrotropin receptor encode truncated polypeptides without a membrane spanning domain.","volume":"3","author":"Hunt","year":"1995","journal-title":"Endocrine"},{"key":"2020071612053021500_R43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1006\/clin.1994.1059","article-title":"TSH and TSH receptor antibody binding sites in fibroblasts of pretibial myxedema are related to the extracellular domain of entire TSH receptor.","volume":"71","author":"Chang","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"2020071612053021500_R44","first-page":"1384","article-title":"Thyrotropin receptor antisera for the detection of immunoreactive protein species in retroocular fibroblasts obtained from patients with Graves\u2019 ophthalmopathy.","volume":"78","author":"Burch","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/thy.1997.7.3","article-title":"TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves\u2019 ophthalmopathy and pretibial myxedema.","volume":"7","author":"Stadlmayr","year":"1997","journal-title":"Thyroid"},{"key":"2020071612053021500_R46","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1210\/jcem.82.6.2003","article-title":"Thyrotropin receptor transcripts in human adipose tissue.","volume":"82","author":"Crisp","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R47","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1530\/eje.0.1360599","article-title":"Analysis of human thyrotropin receptor gene expression and immunoreactivity in human orbital tissue.","volume":"136","author":"Spitzweg","year":"1997","journal-title":"Eur J Endocrinol"},{"key":"2020071612053021500_R48","first-page":"998","article-title":"Thyrotropin receptor expression in Graves\u2019 orbital adipose\/connective tissues: potential autoantigen in Graves\u2019 ophthalmopathy.","volume":"83","author":"Bahn","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R49","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1089\/thy.1998.8.411","article-title":"The thyrotropin receptor in thyroid eye disease.","volume":"8","author":"Ludgate","year":"1998","journal-title":"Thyroid"},{"key":"2020071612053021500_R50","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.4049\/jimmunol.160.3.1458","article-title":"Genetic immunization against the human thyrotropin receptor causes thyroiditis and allows production of monoclonal antibodies recognizing the native receptor.","volume":"160","author":"Costagliola","year":"1998","journal-title":"J Immunol"},{"key":"2020071612053021500_R51","first-page":"2557","article-title":"Differentiation of orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor.","volume":"84","author":"Valyasevi","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1677\/jme.0.0130011","article-title":"Overexpression of the extracellular domain of the thyrotropin receptor in bacteria \u2014 production of thyrotropin-binding inhibiting immunoglobulins.","volume":"13","author":"Costagliola","year":"1994","journal-title":"J Mol Endocrinol"},{"key":"2020071612053021500_R53","first-page":"3427","article-title":"Immunoglobulin A class fibroblast antibodies in patients with Graves\u2019 disease and pretibial myxedema.","volume":"80","author":"Arnold","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R54","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1089\/thy.1996.6.275","article-title":"Studies of retroorbital tissue xenografts from patients with Graves\u2019 ophthalmopathy in severe combined immunodeficient (SCID) mice: detection of thyroid-stimulating antibody.","volume":"6","author":"Mori","year":"1996","journal-title":"Thyroid"},{"key":"2020071612053021500_R55","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1210\/endo.137.11.8895327","article-title":"Transfer of thyroiditis, with syngeneic spleen cells sensitized with the human thyrotropin receptor, to naive balb\/c and nod mice.","volume":"137","author":"Costagliola","year":"1996","journal-title":"Endocrinology"},{"key":"2020071612053021500_R56","first-page":"256","article-title":"A genomic point mutation in the extracellular domain of the thyrotropin receptor in patients with Graves\u2019 ophthalmopathy.","volume":"78","author":"Bahn","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1089\/thy.1995.5.89","article-title":"A polymorphism in the extracellular domain of the thyrotropin receptor is highly associated with autoimmune thyroid disease in females.","volume":"5","author":"Cuddihy","year":"1995","journal-title":"Thyroid"},{"key":"2020071612053021500_R58","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/0167-4781(93)90024-8","article-title":"A heritable point mutation in an extracellular domain on the TSH receptor involved in the interaction with Graves\u2019 immunoglobulins.","volume":"1216","author":"Bohr","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"2020071612053021500_R59","first-page":"1032","article-title":"Lack of association between a polymorphism in the coding region of the thyrotropin receptor gene and Graves\u2019 disease.","volume":"80","author":"Watson","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/thy.1997.7.31","article-title":"No association between a thyrotropin receptor gene polymorphism and Graves\u2019 disease in the female population.","volume":"7","author":"Kotsa","year":"1997","journal-title":"Thyroid"},{"key":"2020071612053021500_R61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0014-5793(88)80402-2","article-title":"Human orbital tissue and thyroid membranes express a 64 kDa protein which is recognized by autoantibodies in the serum of patients with thyroid-associated ophthalmopathy.","volume":"232","author":"Salvi","year":"1988","journal-title":"FEBS Lett"},{"key":"2020071612053021500_R62","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jcem-72-6-1375","article-title":"Cloning and sequencing of a novel 64 kDa autoantigen recognized by patients with autoimmune thyroid disease.","volume":"72","author":"Dong","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R63","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2265.1991.tb00941.x","article-title":"A 64 KDa membrane antigen is a recurrent epitope for natural autoantibodies in patients with Graves\u2019 thyroid and ophthalmic disease.","volume":"35","author":"Kendler","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R64","first-page":"1226","article-title":"Native gel electrophoresis of the 64 kDa protein shows that is eye specific and an important target for autoantibodies in patients with thyroid-associated ophthalmopathy.","volume":"80","author":"Wall","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R65","first-page":"444","article-title":"The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves\u2019 hyperthyroidism.","volume":"83","author":"Kubota","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R66","first-page":"1255","article-title":"Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves\u2019 hyperthyroidism.","volume":"84","author":"Gunji","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R67","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/thy.1998.8.175","article-title":"Reevaluation of the prevalences of serum autoantibodies reactive with \u201c64-kd eye muscle proteins\u201d in patients with thyroid-associated ophthalmopathy.","volume":"8","author":"Kubota","year":"1998","journal-title":"Thyroid"},{"key":"2020071612053021500_R68","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/thy.1998.8.553","article-title":"Role of the eye muscles in thyroid eye disease: identification of the principal autoantigens.","volume":"8","author":"Gunji","year":"1998","journal-title":"Thyroid"},{"key":"2020071612053021500_R69","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1006\/clin.1995.1143","article-title":"Identification of antigenic epitopes of 1D antigen recognized by antibodies in the serum of patients with thyroid-associated ophthalmopathy.","volume":"77","author":"Zhang","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"key":"2020071612053021500_R70","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1006\/clin.1996.0119","article-title":"Tissue distribution and quantitation of a gene expressing a 64 kDa antigen associated with thyroid-associated ophthalmopathy.","volume":"80","author":"Zhang","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"key":"2020071612053021500_R71","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/thy.1998.8.167","article-title":"Prevalence and significance of antibodies reactive with eye muscle membrane antigens in sera from patients with Graves\u2019 ophthalmopathy and other thyroid and nonthyroid diseases.","volume":"8","author":"Wu","year":"1998","journal-title":"Thyroid"},{"key":"2020071612053021500_R72","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0161-6420(95)31066-4","article-title":"Serum antibodies reactive with eye muscle membrane antigens are detected in patients with nonspecific orbital inflammation.","volume":"102","author":"Atabay","year":"1995","journal-title":"Ophthalmology"},{"key":"2020071612053021500_R73","first-page":"685","article-title":"Human histocompatibility leukocyte antigen-DR and heat shock protein-70 expression in eye muscle tissue in thyroid associated ophthalmopathy.","volume":"80","author":"Hiromatsu","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R74","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/BF03349737","article-title":"IgA autoantibodies against human eye muscle antigen detected by Western blotting and immunohistochemical methods in Graves\u2019 disease.","volume":"18","author":"Molnar","year":"1995","journal-title":"J Endocrinol Invest"},{"key":"2020071612053021500_R75","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/thy.1998.8.311","article-title":"Possible involvement of Fas-mediated apoptosis in eye muscle tissue from patients with thyroid-associated ophthalmopathy.","volume":"8","author":"Koga","year":"1998","journal-title":"Thyroid"},{"key":"2020071612053021500_R76","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2265.1995.tb02597.x","article-title":"Natural history of thyroid-associated ophthalmopathy.","volume":"42","author":"Perros","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R77","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0002-9394(14)70585-9","article-title":"The treatment of Graves\u2019 ophthalmopathy in an incidence cohort.","volume":"121","author":"Bartley","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"2020071612053021500_R78","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0002-9394(14)70276-4","article-title":"Clinical features of Graves\u2019 ophthalmopathy in an incidence cohort.","volume":"121","author":"Bartley","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"2020071612053021500_R79","first-page":"1027","article-title":"The study of visual evoked potentials in patients with thyroid-associated ophthalmopathy identifies asymptomatic optic nerve involvement.","volume":"82","author":"Salvi","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R80","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach.","volume":"73","author":"Mourits","year":"1989","journal-title":"Br J Ophthalmol"},{"key":"2020071612053021500_R81","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy.","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R82","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/thy.1992.2.235","article-title":"Classification of eye changes of Graves\u2019 disease.","volume":"2","author":"Pinchera","year":"1992","journal-title":"Thyroid"},{"key":"2020071612053021500_R83","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/thy.1998.8.539","article-title":"The measurement of change in Graves\u2019 ophthalmopathy.","volume":"8","author":"Gorman","year":"1998","journal-title":"Thyroid"},{"key":"2020071612053021500_R84","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0161-6420(93)31607-6","article-title":"A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves\u2019 ophthalmopathy.","volume":"100","author":"Prummel","year":"1993","journal-title":"Ophthalmology"},{"key":"2020071612053021500_R85","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2265.1990.tb00463.x","article-title":"Urinary glycosaminoglycans in Graves\u2019 ophthalmopathy.","volume":"33","author":"Kahaly","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R86","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF03344962","article-title":"Plasma glycosaminoglycans in endocrine ophthalmopathy.","volume":"17","author":"Kahaly","year":"1994","journal-title":"J Endocrinol Invest"},{"key":"2020071612053021500_R87","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1089\/thy.1998.8.429","article-title":"Glycosaminoglycans in thyroid eye disease.","volume":"8","author":"Kahaly","year":"1998","journal-title":"Thyroid"},{"key":"2020071612053021500_R88","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/thy.1995.5.185","article-title":"MR T2 relaxation time for the assessment of retrobulbar inflammation in Graves\u2019 ophthalmopathy.","volume":"5","author":"Utech","year":"1995","journal-title":"Thyroid"},{"key":"2020071612053021500_R89","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1210\/jcem.79.6.7989493","article-title":"[111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves\u2019 disease: a parameter for disease activity?","volume":"79","author":"Postema","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R90","first-page":"550","article-title":"Indium-111-pentreotide scintigraphy in Graves\u2019 ophthalmopathy.","volume":"36","author":"Kahaly","year":"1995","journal-title":"J Nucl Med"},{"key":"2020071612053021500_R91","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00003072-199503000-00010","article-title":"Somatostatin receptors in the orbit.","volume":"20","author":"Durak","year":"1995","journal-title":"Clin Nucl Med"},{"key":"2020071612053021500_R92","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/00006231-199511000-00006","article-title":"111In-octreotide imaging in patients with long-standing Graves\u2019 ophthalmopathy.","volume":"16","author":"Bohuslavziki","year":"1995","journal-title":"Nucl Med Commun"},{"key":"2020071612053021500_R93","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/thy.1997.7.21","article-title":"Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide.","volume":"7","author":"Moncayo","year":"1997","journal-title":"Thyroid"},{"key":"2020071612053021500_R94","first-page":"533","article-title":"Indium-111-pentreotide in Graves\u2019 disease.","volume":"39","author":"Kahaly","year":"1998","journal-title":"J Nucl Med"},{"key":"2020071612053021500_R95","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2265.1999.00681.x","article-title":"Octreotide-scintigraphy is a disease-activity parameter in Graves\u2019 ophthalmopathy.","volume":"50","author":"Gerding","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R96","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/thy.1998.8.433","article-title":"Octreotide scintigraphy in thyroidal and orbital Graves\u2019 disease.","volume":"8","author":"Wiersinga","year":"1998","journal-title":"Thyroid"},{"key":"2020071612053021500_R97","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0161-6420(91)32099-2","article-title":"Graves\u2019 exophthalmos unrelated to extraocular muscle enlargement. Superior rectus muscle inflammation may induce venous obstruction.","volume":"98","author":"Hudson","year":"1991","journal-title":"Ophthalmology"},{"key":"2020071612053021500_R98","first-page":"20","article-title":"Doppler ultrasound findings in patients with thyroid ophthalmopathology.","volume":"91","author":"Benning","year":"1994","journal-title":"Ophthalmology"},{"key":"2020071612053021500_R99","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1089\/thy.1998.8.545","article-title":"Immunomodulatory treatment of Graves\u2019 ophthalmopathy.","volume":"8","author":"Prummel","year":"1998","journal-title":"Thyroid"},{"key":"2020071612053021500_R100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2265.1998.00487.x","article-title":"Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey.","volume":"49","author":"Weetman","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R101","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2265.1998.00563.x","article-title":"Current management of thyroid-associated ophthalmopathy.","volume":"49","author":"Kendall-Taylor","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R102","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/jcem-37-2-276","article-title":"Supervoltage orbital radiotherapy for Graves\u2019 ophthalmopathy.","volume":"37","author":"Donaldson","year":"1973","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R103","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198911163212002","article-title":"Prednisone and cyclosporine in the treatment of severe Graves\u2019 ophthalmopathy.","volume":"321","author":"Prummel","year":"1989","journal-title":"N Engl J Med"},{"key":"2020071612053021500_R104","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2265.1997.2070991.x","article-title":"Clinical activity score as a guide in the management of patients with Graves\u2019 orbitopathy.","volume":"47","author":"Rose","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R105","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/bjo.80.10.922","article-title":"Thyroid eye disease.","volume":"80","author":"Char","year":"1996","journal-title":"Br J Ophthalmol"},{"key":"2020071612053021500_R106","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0161-6420(79)35290-3","article-title":"Orthoptics in Graves\u2019 disease.","volume":"86","author":"Kulla","year":"1979","journal-title":"Ophthalmology"},{"key":"2020071612053021500_R107","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/1043-2760(90)90095-K","article-title":"Immunosuppressive treatment of Graves\u2019 ophthalmopathy.","volume":"1","author":"Wiersinga","year":"1990","journal-title":"Trends Endocrinol Metab"},{"key":"2020071612053021500_R108","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1055\/s-0029-1211086","article-title":"Glucocorticoid therapy of Graves\u2019 ophthalmopathy.","volume":"97","author":"Bartalena","year":"1991","journal-title":"Exp Clin Endocrinol"},{"key":"2020071612053021500_R109","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1172\/JCI111642","article-title":"Dexamethasone regulation of glycosaminoglycan synthesis in cultured human fibroblasts: similar effects of glucocorticoid and thyroid hormone therapy.","volume":"64","author":"Smith","year":"1984","journal-title":"J Clin Invest"},{"key":"2020071612053021500_R110","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1210\/jcem-69-5-1019","article-title":"Hormonal regulation of hyaluronate synthesis in cultured fibroblasts; evidence for differences between retroocular and dermal fibroblasts.","volume":"69","author":"Smith","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R111","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","article-title":"Ciclosporin and prednisone v. prednisone in treatment of Graves\u2019 ophthalmopathy: a controlled, randomized and prospective study.","volume":"16","author":"Kahaly","year":"1986","journal-title":"Eur J Clin Invest"},{"key":"2020071612053021500_R112","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0140-6736(93)92001-A","article-title":"Randomised double-blind trial of prednisone vs. radiotherapy in Graves\u2019 ophthalmopathy.","volume":"342","author":"Prummel","year":"1993","journal-title":"Lancet"},{"key":"2020071612053021500_R113","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1507\/endocrj.42.441","article-title":"Thyroid stimulating antibody in sera of Graves\u2019 ophthalmopathy patients as a possible marker for predicting the efficacy of methylprednisolone pulse therapy.","volume":"42","author":"Mori","year":"1995","journal-title":"Endocr J"},{"key":"2020071612053021500_R114","first-page":"3790","article-title":"Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-Phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves\u2019 ophthalmopathy.","volume":"83","author":"Colao","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2265.1987.tb00836.x","article-title":"Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves\u2019 ophthalmopathy: a comparative study.","volume":"27","author":"Marcocci","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R116","first-page":"301","author":"Pinchera","year":"1984"},{"key":"2020071612053021500_R117","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/thy.1998.8.439","article-title":"Orbital radiotherapy for Graves\u2019 ophthalmopathy.","volume":"8","author":"Bartalena","year":"1998","journal-title":"Thyroid"},{"key":"2020071612053021500_R118","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/BF01711917","article-title":"Immunosuppressant therapy of thyroid eye disease.","volume":"66","author":"Kahaly","year":"1988","journal-title":"Klin Wochenschr"},{"key":"2020071612053021500_R119","first-page":"131","author":"Marcocci","year":"1993"},{"key":"2020071612053021500_R120","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1055\/s-0029-1211088","article-title":"Role of orbital radiotherapy in the treatment of Graves\u2019 ophthalmopathy.","volume":"97","author":"Marcocci","year":"1991","journal-title":"Exp Clin Endocrinol"},{"key":"2020071612053021500_R121","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0360-3016(90)90532-O","article-title":"Prognostic factors in the radiotherapy if Graves\u2019 ophthalmopathy.","volume":"19","author":"Petersen","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020071612053021500_R122","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1148\/radiology.196.3.7644656","article-title":"Graves\u2019 ophthalmopathy: MR evaluation of 10-Gy vs. 24-Gy irradiation combined with systemic corticosteroids.","volume":"196","author":"Nakahara","year":"1995","journal-title":"Radiology"},{"key":"2020071612053021500_R123","first-page":"102","volume":"85","author":"Kahaly","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R124","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1210\/jcem-56-6-1139","article-title":"Orbital cobalt irradiation combined with systemic corticosteroids for Graves\u2019 ophthalmopathy: comparison with systemic corticosteroids alone.","volume":"56","author":"Bartalena","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R125","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0002-9394(14)76869-2","article-title":"Radiation retinopathy after standard radiotherapy for thyroid-related ophthalmopathy.","volume":"112","author":"Miller","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"2020071612053021500_R126","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/archopht.1984.01040031193016","article-title":"Radiation retinopathy after orbital irradiation for Graves\u2019 ophthalmopathy.","volume":"102","author":"Kinyoun","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"2020071612053021500_R127","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1210\/jcem.80.8.7677916","article-title":"Radiation and Graves\u2019 ophthalmopathy (letter).","volume":"80","author":"Orcutt","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R128","author":"Tallstedt"},{"key":"2020071612053021500_R129","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(05)78494-4","article-title":"Transitory blindness after retrobulbar irradiation of Graves\u2019 ophthalmopathy.","volume":"351","author":"Nygaard","year":"1998","journal-title":"Lancet"},{"key":"2020071612053021500_R130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0167-8140(95)01670-8","article-title":"Probable risk of tumor induction after retro-orbital irradiation for Graves\u2019 ophthalmopathy.","volume":"38","author":"Snijders-Keilholz","year":"1996","journal-title":"Radiother Oncol"},{"key":"2020071612053021500_R131","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0167-8140(96)01771-9","article-title":"Probable risk of tumor induction after retro-orbital irradiation for Graves\u2019 ophthalmopathy (letter).","volume":"40","author":"Blank","year":"1996","journal-title":"Radiother Oncol"},{"key":"2020071612053021500_R132","author":"Gorman","year":"1999"},{"key":"2020071612053021500_R133","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/jcem.80.2.7852487","article-title":"Retrobulbar radiation in Graves\u2019 ophthalmopathy.","volume":"80","author":"Wiersinga","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R134","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/BF03347943","article-title":"Orbital radiotherapy combined with high-dose systemic glucocorticoids for Graves\u2019 ophthalmopathy is more effective than orbital radiotherapy alone: results of a prospective study.","volume":"14","author":"Marcocci","year":"1991","journal-title":"J Endocrinol Invest"},{"key":"2020071612053021500_R135","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0002-9394(14)73194-0","article-title":"Results of transantral orbital decompression in 428 patients with severe Graves\u2019 ophthalmopathy.","volume":"116","author":"Garrity","year":"1993","journal-title":"Am J Ophthalmol"},{"key":"2020071612053021500_R136","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0161-6420(13)31236-6","article-title":"Graves opthalmopathy. Results of transantral orbital decompression performed primarily for cosmetic indications.","volume":"101","author":"Fatourechi","year":"1994","journal-title":"Ophthalmology"},{"key":"2020071612053021500_R137","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0161-6420(94)31343-1","article-title":"Orbital decompression for disfiguring exophthalmus in thyroid orbitopathy.","volume":"110","author":"Lyons","year":"1994","journal-title":"Ophthalmology"},{"key":"2020071612053021500_R138","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/bjo.81.1.41","article-title":"Coronal approach for rehabilitative orbital decompression in Graves\u2019 ophthalmopathy.","volume":"81","author":"Kalmann","year":"1997","journal-title":"Br J Ophthalmol"},{"key":"2020071612053021500_R139","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0161-6420(85)34079-4","article-title":"Current trends in orbital decompression.","volume":"92","author":"McCord","year":"1985","journal-title":"Ophthalmology"},{"key":"2020071612053021500_R140","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1089\/thy.1998.8.447","article-title":"Surgical treatment of thyroid eye disease.","volume":"8","author":"Tallstedt","year":"1998","journal-title":"Thyroid"},{"key":"2020071612053021500_R141","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00002341-199709000-00001","article-title":"The risk of diplopia following orbital floor and medial wall decompression in subtypes of ophthalmic Graves\u2019 disease.","volume":"13","author":"Nunery","year":"1997","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"2020071612053021500_R142","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/eye.1995.143","article-title":"Long-term visual outcome following orbital decompression for dysthyroid eye disease.","volume":"9","author":"Hutchinson","year":"1995","journal-title":"Eye"},{"key":"2020071612053021500_R143","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/archotol.1994.01880320033008","article-title":"Orbital decompression in Graves\u2019 disease.","volume":"120","author":"Weissman","year":"1994","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2020071612053021500_R144","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1097\/00005537-199811000-00011","article-title":"Balanced orbital de-compression for Graves\u2019 ophthalmopathy.","volume":"108","author":"Shepard","year":"1998","journal-title":"Laryngoscope"},{"key":"2020071612053021500_R145","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0161-6420(93)31589-7","article-title":"Orbital fat removal. Decompression for Graves\u2019 orbitopathy.","volume":"100","author":"Trokel","year":"1993","journal-title":"Ophthalmology"},{"key":"2020071612053021500_R146","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00006534-199104000-00004","article-title":"Transpalpebral decompression of endocrine ophthalmopathy (Graves\u2019 disease) by removal of intraorbital fat: experience with 147 operations over 5 years.","volume":"87","author":"Olivari","year":"1991","journal-title":"Plast Reconstr Surg"},{"key":"2020071612053021500_R147","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/112067219800800408","article-title":"Treatment of proptosis with fat removal orbital decompression in Graves\u2019 ophthalmopathy.","volume":"8","author":"Adenis","year":"1998","journal-title":"Eur J Ophthalmol"},{"key":"2020071612053021500_R148","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00006534-199707000-00007","article-title":"The \u201ctriple technique\u201d for treating stable Graves\u2019 ophthalmopathy.","volume":"100","author":"Tremolada","year":"1997","journal-title":"Plast Reconstr Surg"},{"key":"2020071612053021500_R149","first-page":"25","author":"Borel","year":"1985"},{"key":"2020071612053021500_R150","first-page":"909","volume":"1","journal-title":"Lancet"},{"key":"2020071612053021500_R151","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0140-6736(83)90514-7","article-title":"Cyclosporine improves Graves\u2019 ophthalmopathy.","volume":"3","author":"Weetman","year":"1983","journal-title":"Lancet"},{"key":"2020071612053021500_R152","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/bmj.2.6191.667-c","article-title":"Exophthalmos and pretibial myxoedema not responding to plasmapheresis.","volume":"2","author":"Dandona","year":"1979","journal-title":"Br Med J"},{"key":"2020071612053021500_R153","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1530\/acta.0.1110030","article-title":"Beneficial effects of intensive plasma exchange followed by immunosuppressive theraoy in severe Graves\u2019 ophthalmopathy.","volume":"111","author":"Glinoer","year":"1986","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071612053021500_R154","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/jca.2920050405","article-title":"Plasma exchange in endocrine ophthalmopathy.","volume":"5","author":"Berlin","year":"1990","journal-title":"J Clin Apheresis"},{"key":"2020071612053021500_R155","first-page":"245","article-title":"Plasma exchange in conjunction with immunosuppressive drug therapy in the treatment of endocrine exophthalmos.","volume":"6","author":"Sawers","year":"1981","journal-title":"J Clin Lab Immunol"},{"key":"2020071612053021500_R156","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2265.1983.tb02878.x","article-title":"An evaluation of plasma exchange for Graves\u2019 ophthalmopathy.","volume":"18","author":"Kelly","year":"1983","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R157","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJM199205213262109","article-title":"Desperate diseases and plasmapheresis.","volume":"326","author":"Campion","year":"1992","journal-title":"N Engl J Med"},{"key":"2020071612053021500_R158","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"patients.","volume":"20","author":"Krenning","year":"1000","journal-title":"Eur J Nucl Med"},{"key":"2020071612053021500_R159","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/thy.1998.8.443","article-title":"Somatostatin analogues in the treatment of thyroid eye disease.","volume":"8","author":"Krassas","year":"1998","journal-title":"Thyroid"},{"key":"2020071612053021500_R160","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/bmj.304.6820.158","article-title":"Octreotide and Graves\u2019 ophthalmopathy and pretibial myxoedema.","volume":"304","author":"Chang","year":"1992","journal-title":"Br Med J"},{"key":"2020071612053021500_R161","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2265.1995.tb02682.x","article-title":"Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease.","volume":"42","author":"Krassas","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R162","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/thy.1996.6.381","article-title":"The effect of somatostatin vs. corticosteroid in the treatment of Graves\u2019 ophthalmopathy.","volume":"6","author":"Kung","year":"1996","journal-title":"Thyroid"},{"key":"2020071612053021500_R163","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/thy.1996.6.283","article-title":"Effects of octreotide treatment on Graves\u2019 ophthalmopathy and circulating sICAM-1 levels.","volume":"6","author":"Ozata","year":"1996","journal-title":"Thyroid"},{"key":"2020071612053021500_R164","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1530\/eje.0.1360416","article-title":"Lanreotide in the treatment of patients with thyroid eye disease.","volume":"136","author":"Krassas","year":"1997","journal-title":"Eur J Endocrinol"},{"key":"2020071612053021500_R165","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/thy.1999.9.47","article-title":"Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.","volume":"9","author":"Krassas","year":"1999","journal-title":"Thyroid"},{"key":"2020071612053021500_R166","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(86)90698-7","article-title":"Somatomedin C in the pathogenesis of malignant exophthalmos of endocrine origin.","volume":"1","author":"Hansson","year":"1986","journal-title":"Lancet"},{"key":"2020071612053021500_R167","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0140-6736(05)78212-X","article-title":"Intravenous immunoglobulins and transforming growth factor-\u03b2.","volume":"351","author":"Kekow","year":"1998","journal-title":"Lancet"},{"key":"2020071612053021500_R168","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/acta.0.1260013","article-title":"High-dose intravenous immunoglobulin treatment in Graves\u2019 ophthalmopathy.","volume":"126","author":"Antonelli","year":"1992","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071612053021500_R169","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2249.1996.d01-854.x","article-title":"Randomized trial of intravenous immunoglobulins versus prednisolone in Graves\u2019 ophthalmopathy.","volume":"106","author":"Kahaly","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"2020071612053021500_R170","author":"Seppel","year":"1996"},{"key":"2020071612053021500_R171","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/thy.1997.7.579","article-title":"Intravenous immunoglobulin vs. corticosteroid in treatment of Graves\u2019 ophthalmopathy.","volume":"7","author":"Baschieri","year":"1997","journal-title":"Thyroid"},{"key":"2020071612053021500_R172","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1055\/s-0029-1210493","article-title":"Positive effect of bromocriptine treatment in Graves\u2019 disease orbitopathy.","volume":"86","author":"Kolodziej-Maciejewska","year":"1985","journal-title":"Exp Clin Endocrinol"},{"key":"2020071612053021500_R173","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/0002-9394(89)90272-9","article-title":"Bromocriptine therapy for thyroid ophthalmopathy.","volume":"107","author":"Lopatynsky","year":"1989","journal-title":"Am J Ophthalmol"},{"key":"2020071612053021500_R174","first-page":"890","article-title":"The effect of metrodinazole on thyroid function and exophthalmos in man.","volume":"16","author":"Harden","year":"1967","journal-title":"Ophthalmology"},{"key":"2020071612053021500_R175","first-page":"19","article-title":"The effect of acupuncture in 40 cases of endocrine ophthalmopathy.","volume":"5","author":"Zesen","year":"1985","journal-title":"J Trad Chinese Med"},{"key":"2020071612053021500_R176","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1530\/acta.0.1240143","article-title":"Acupuncture in the treatment of Graves\u2019 ophthalmopathy. A blinded randomized study.","volume":"124","author":"Rogvi-Hansen","year":"1991","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071612053021500_R177","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0161-6420(99)90071-4","article-title":"Early strabismus surgery for thyroid ophthalmopathy.","volume":"106","author":"Coats","year":"1999","journal-title":"Ophthalmology"},{"key":"2020071612053021500_R178","first-page":"253","author":"Dyer","year":"1984"},{"key":"2020071612053021500_R179","first-page":"85","author":"Putterman","year":"1997"},{"key":"2020071612053021500_R180","first-page":"481","author":"Mourits"},{"key":"2020071612053021500_R181","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0161-6420(92)31866-4","article-title":"Long-term results of adjustable suture surgery for strabismus secondary to thyroid ophthalmopathy.","volume":"99","author":"Lueder","year":"1992","journal-title":"Ophthalmology"},{"key":"2020071612053021500_R182","first-page":"67","article-title":"Treatment of thyroid ocular myopathy with adjustable and nonadjustable suture strabismus surgery.","volume":"91","author":"Kraus","year":"1993","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2020071612053021500_R183","first-page":"1","article-title":"Graves\u2019 ophthalmopathy: an ophthalmologist\u2019s perspective.","volume":"15","author":"Garrity","year":"1992","journal-title":"Thyroid Today"},{"key":"2020071612053021500_R184","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/bjo.82.5.528","article-title":"Botulinum toxin A treatment of overactive corrugator supercilii in thyroid eye disease.","volume":"82","author":"Olver","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"2020071612053021500_R185","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/bjo.75.6.344","article-title":"Lid lengthening by sclera interposition for eyelid retraction in Graves\u2019 ophthalmopathy.","volume":"75","author":"Mourits","year":"1991","journal-title":"Br J Ophthalmol"},{"key":"2020071612053021500_R186","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF03349519","article-title":"Comparison of RA131I treatment protocols for Graves\u2019 disease.","volume":"13","author":"DeGroot","year":"1990","journal-title":"J Endocrinol Invest"},{"key":"2020071612053021500_R187","first-page":"2136","article-title":"Effect on exophthalmos of various methods of treatment of Graves\u2019 disease.","volume":"247","author":"Gwynup","year":"1982","journal-title":"JAMA"},{"key":"2020071612053021500_R188","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0140-6736(89)90945-8","article-title":"Ophthalmopathy and thyroid stimulation.","volume":"2","author":"Karlsson","year":"1989","journal-title":"Lancet"},{"key":"2020071612053021500_R189","first-page":"185","author":"Prummel","year":"1989"},{"key":"2020071612053021500_R190","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/archinte.1990.00390170124027","article-title":"Effect of abnormal thyroid function on the severity of Graves\u2019 ophthalmopathy.","volume":"150","author":"Prummel","year":"1990","journal-title":"Arch Intern Med"},{"key":"2020071612053021500_R191","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/thy.1992.2.171","article-title":"Relationship between Graves\u2019 ophthalmopathy and type of treatment of Graves\u2019 hyperthyroidism.","volume":"2","author":"Marcocci","year":"1992","journal-title":"Thyroid"},{"key":"2020071612053021500_R192","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","article-title":"Relation between therapy for hyperthyroidism and the course of Graves\u2019 ophthalmopathy.","volume":"338","author":"Bartalena","year":"1998","journal-title":"N Engl J Med"},{"key":"2020071612053021500_R193","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/thy.1997.7.369","article-title":"Clinical features of patients with Graves\u2019 disease undergoing remission after antithyroid drug treatment.","volume":"7","author":"Vitti","year":"1997","journal-title":"Thyroid"},{"key":"2020071612053021500_R194","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199104043241403","article-title":"Administration of thyroxine in Graves\u2019 disease: effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.","volume":"324","author":"Hashizume","year":"1991","journal-title":"N Engl J Med"},{"key":"2020071612053021500_R195","first-page":"120","article-title":"Treatment of Graves\u2019 disease by carbimazole: high dose with thyroxine compared to titration dose.","volume":"131","author":"Edmonds","year":"1994","journal-title":"J Endocrinol"},{"key":"2020071612053021500_R196","first-page":"1481","article-title":"Lack of effect of thyroxine administration on elevated thyroid stimulating receptor antibody levels in treated Graves\u2019 disease patients.","volume":"80","author":"Tamai","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R197","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJM199601253340403","article-title":"Lack of effect of thyroxine in patients with Graves\u2019 hyperthyroidism who are treated with an antithyroid drug.","volume":"334","author":"McIver","year":"1996","journal-title":"N Engl J Med"},{"key":"2020071612053021500_R198","first-page":"2410","author":"Lucas"},{"key":"2020071612053021500_R199","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2265.1998.00466.x","article-title":"TSH suppression combined with carbimazole for Graves\u2019 disease: effect on remission and relapse rates.","volume":"48","author":"Pujol","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R200","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF03347329","article-title":"Ablative or non-ablative therapy for Graves\u2019 hyperthyroidism in patients with ophthalmopathy?","volume":"21","author":"Marcocci","year":"1998","journal-title":"J Endocrinol Invest"},{"key":"2020071612053021500_R201","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1210\/jcem-70-6-1518","article-title":"Current trends in the management of Graves\u2019 disease.","volume":"70","author":"Solomon","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R202","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1210\/jcem.80.2.7852485","article-title":"Radioiodine therapy does not aggravate Graves\u2019 ophthalmopathy.","volume":"80","author":"Gorman","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R203","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jcem.80.2.7852486","article-title":"Radioiodine may be bad for Graves\u2019 ophthalmopathy, but \u2026 .","volume":"80","author":"Pinchera","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R204","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/01676839609150237","article-title":"Radioiodine and thyroid-associated ophthalmopathy.","volume":"15","author":"Marcocci","year":"1996","journal-title":"Orbit"},{"key":"2020071612053021500_R205","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM198911163212001","article-title":"Use of corticosteroids to prevent progression of Graves\u2019 ophthalmopathy after radioiodine therapy for hyperthyroidism.","volume":"321","author":"Bartalena","year":"1989","journal-title":"N Engl J Med"},{"key":"2020071612053021500_R206","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199206253262603","volume":"326","author":"Tallstedt","journal-title":"N Engl J Med"},{"key":"2020071612053021500_R207","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1530\/eje.0.1300494","article-title":"Does early administration of thyroxine reduce the development of Graves\u2019 ophthalmopathy after radioiodine treatment?","volume":"130","author":"Tallstedt","year":"1994","journal-title":"Eur J Endocrinol"},{"key":"2020071612053021500_R208","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/thy.1997.7.241","article-title":"Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective.","volume":"7","author":"Tallstedt","year":"1997","journal-title":"Thyroid"},{"key":"2020071612053021500_R209","first-page":"241","article-title":"Influencia del tratamento del hipertiroidismo en el curso del exoftalmos.","volume":"44","author":"Va\u0300zquez-Cha\u0300vez","year":"1992","journal-title":"Rev Invest Clin"},{"key":"2020071612053021500_R210","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJM199805213382114","article-title":"Therapy for hyperthyroidism and Graves\u2019 ophthalmopathy (letter).","volume":"338","author":"Gorman","year":"1998","journal-title":"N Engl J Med"},{"key":"2020071612053021500_R211","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJM199801083380209","article-title":"Preventing Graves\u2019 ophthalmopathy.","volume":"338","author":"Wiersinga","year":"1998","journal-title":"N Engl J Med"},{"key":"2020071612053021500_R212","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-129-8-199810150-00010","article-title":"Cigarette smoking and treatment outcomes in Graves ophthalmopathy.","volume":"129","author":"Bartalena","year":"1998","journal-title":"Ann Intern Med"},{"key":"2020071612053021500_R213","first-page":"542","article-title":"The incidence of ophthalmopathy after radioiodine therapy for Graves\u2019 disease: prognostic factors and the role of methimazole.","volume":"79","author":"Kung","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R214","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00060793-199610000-00010","article-title":"Recent progress in Graves\u2019 ophthalmopathy.","volume":"3","author":"Marcocci","year":"1996","journal-title":"Curr Opin Endocrinol Metab"},{"key":"2020071612053021500_R215","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1210\/jcem-37-5-703","article-title":"Graves\u2019 ophthalmopathy following external neck irradiation for nonthyroidal neoplastic disease.","volume":"37","author":"Wasnich","year":"1973","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R216","first-page":"1393","article-title":"Ophthalmopathy after neck irradiation therapy for Hodgkin\u2019s disease.","volume":"63","author":"Jackson","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"2020071612053021500_R217","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/thy.1996.6.345","article-title":"Graves\u2019 disease occurring after subacute thyroiditis: report of a case and review of the literature.","volume":"6","author":"Bartalena","year":"1996","journal-title":"Thyroid"},{"key":"2020071612053021500_R218","first-page":"3634","article-title":"Sequential changes in serum thyroid peroxidase following radioiodine therapy of patients with differentiated thyroid carcinoma.","volume":"80","author":"Ozata","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R219","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem-29-2-231","volume":"29","author":"Pinchera","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R220","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1530\/acta.0.1220233","article-title":"Peripheral blood T cell activation after radioiodine treatment for Graves\u2019 disease.","volume":"122","author":"Teng","year":"1990","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071612053021500_R221","first-page":"517","article-title":"Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves\u2019 disease.","volume":"4","author":"Aizawa","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R222","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJM199801083380201","article-title":"Therapy for hyperthyroidism and Graves\u2019 ophthalmopathy (letter).","volume":"338","author":"Bartalena","year":"1998","journal-title":"N Engl J Med"},{"key":"2020071612053021500_R223","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0002-9343(89)80485-1","article-title":"Treatment of Graves\u2019 disease and the course of ophthalmopathy.","volume":"87","author":"Sridama","year":"1989","journal-title":"Am J Med"},{"key":"2020071612053021500_R224","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/BF01658552","article-title":"The influence of surgery on endocrine ophthalmopathy.","volume":"14","author":"Frilling","year":"1990","journal-title":"World J Surg"},{"key":"2020071612053021500_R225","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/bjs.1800800921","article-title":"Graves\u2019 ophthalmopathy after subtotal thyroidectomy and radioiodine therapy.","volume":"80","author":"Ferna\u0300ndez-Sa\u0300nchez","year":"1993","journal-title":"Br J Surg"},{"key":"2020071612053021500_R226","first-page":"1108","article-title":"Surgery still has a role in Graves\u2019 hyperthyroidism.","volume":"114","author":"Patwardhan","year":"1993","journal-title":"Surgery"},{"key":"2020071612053021500_R227","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1530\/eje.0.1320406","article-title":"Retrospective evaluation of subtotal and total thyroidectomy in Graves\u2019 disease with and without endocrine ophthalmopathy.","volume":"132","author":"Winsa","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"2020071612053021500_R228","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0039-6060(96)80049-3","article-title":"Surgical treatment of Graves\u2019 disease: subtotal or total thyroidectomy?","volume":"120","author":"Miccoli","year":"1996","journal-title":"Surgery"},{"key":"2020071612053021500_R229","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s002689900458","article-title":"Effect of subtotal thyroidectomy on natural history of ophthalmopathy in Graves\u2019 disease.","volume":"22","author":"Abe","year":"1998","journal-title":"World J Surg"},{"key":"2020071612053021500_R230","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1046\/j.1365-2265.1999.00843.x","article-title":"The course of Graves\u2019 ophthalmopathy is not influenced by near-total thyroidectomy: a case-control study.","volume":"51","author":"Marcocci","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R231","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1530\/acta.0.1190373","article-title":"Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome.","volume":"119","author":"Pacini","year":"1988","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071612053021500_R232","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/BF03347330","article-title":"Ablative or non-ablative therapy for Graves\u2019 hyperthyroidism in patients with ophthalmopathy?","volume":"21","author":"Weetman","year":"1998","journal-title":"J Endocrinol Invest"},{"key":"2020071612053021500_R233","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/thy.1997.7.259","article-title":"Radioiodine and the immune system.","volume":"7","author":"DeGroot","year":"1997","journal-title":"Thyroid"},{"key":"2020071612053021500_R234","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/01676839609150236","article-title":"Evaluation of thyroid ablative therapy for ophthalmopathy of Graves\u2019 disease.","volume":"15","author":"DeGroot","year":"1996","journal-title":"Orbit"},{"key":"2020071612053021500_R235","first-page":"1","article-title":"Treatment of hyperthyroidism.","volume":"2","author":"Chiovato","year":"1995","journal-title":"Thyroid International"},{"key":"2020071612053021500_R236","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0950-351X(97)80678-7","article-title":"The genetic susceptibility to Graves\u2019 disease.","volume":"11","author":"Tomer","year":"1997","journal-title":"Bailliere\u2019s Clin Endocrinol Metab"},{"key":"2020071612053021500_R237","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/thy.1998.8.407","article-title":"The genetics of thyroid associated ophthalmopathy.","volume":"8","author":"Farid","year":"1998","journal-title":"Thyroid"},{"key":"2020071612053021500_R238","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2265.1993.tb00516.x","article-title":"Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic.","volume":"38","author":"Perros","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R239","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/archopht.1993.01090020051022","article-title":"The initial clinical characteristics of Graves\u2019 orbitopathy vary with age and sex.","volume":"111","author":"Kendler","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"2020071612053021500_R240","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/thy.1998.8.427","article-title":"Clinical presentation of thyroid associated orbitopathy.","volume":"8","author":"Kendall-Taylor","year":"1998","journal-title":"Thyroid"},{"key":"2020071612053021500_R241","first-page":"477","article-title":"The epidemiology characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota.","volume":"92","author":"Bartley","year":"1994","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2020071612053021500_R242","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/thy.1998.8.423","article-title":"Natural history of thyroid eye disease.","volume":"8","author":"Perros","year":"1998","journal-title":"Thyroid"},{"key":"2020071612053021500_R243","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/thy.1994.4.327","article-title":"Cigarette smoking and the thyroid.","volume":"4","author":"Bertelesen","year":"1994","journal-title":"Thyroid"},{"key":"2020071612053021500_R244","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1530\/eje.0.1330507","article-title":"Cigarette smoking and the thyroid.","volume":"133","author":"Bartalena","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"2020071612053021500_R245","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1993.03500040045034","article-title":"Smoking and risk of Graves\u2019 disease.","volume":"269","author":"Prummel","year":"1993","journal-title":"JAMA"},{"key":"2020071612053021500_R246","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/BF03350047","article-title":"More on smoking habits and Graves\u2019 ophthalmopathy.","volume":"12","author":"Bartalena","year":"1989","journal-title":"J Endocrinol Invest"},{"key":"2020071612053021500_R247","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2796.1991.tb00308.x","article-title":"Effects of cigarette smoking on thyroid function and the prevalence of goitre, thyrotoxicosis and autoimmune thyroiditis.","volume":"229","author":"Ericsson","year":"1991","journal-title":"J Intern Med"},{"key":"2020071612053021500_R248","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/0140-6736(90)91315-2","article-title":"Association between Graves\u2019 ophthalmopathy and smoking.","volume":"1","author":"Shine","year":"1990","journal-title":"Lancet"},{"key":"2020071612053021500_R249","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bmj.296.6617.241","article-title":"Postpartum thyroid dysfunction in Mid Glamorgan.","volume":"296","author":"Fung","year":"1988","journal-title":"Br Med J"},{"key":"2020071612053021500_R250","first-page":"161","article-title":"The effect of smoking on the presence of antinuclear antibodies and the morphology of lymphocytes in aged subjects.","volume":"21","author":"Regius","year":"1988","journal-title":"Z Gerontol"},{"key":"2020071612053021500_R251","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2265.1990.tb00898.x","article-title":"A long-term follow-up of post-partum thyroiditis.","volume":"32","author":"Othman","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R252","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/bmj.295.6599.634","article-title":"Is endocrine ophthalmopathy related to smoking?","volume":"295","author":"Hagg","year":"1987","journal-title":"Br Med J"},{"key":"2020071612053021500_R253","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/0140-6736(90)92251-C","article-title":"Association between Graves\u2019 ophthalmopathy and smoking (letter).","volume":"2","author":"Balazs","year":"1990","journal-title":"Lancet"},{"key":"2020071612053021500_R254","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1530\/acta.0.1280156","article-title":"Graves\u2019 disease, endocrine ophthalmopathy and smoking.","volume":"128","author":"Winsa","year":"1993","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071612053021500_R255","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1530\/acta.0.1290147","article-title":"Graves\u2019 ophthalmopathy and tobacco smoking.","volume":"129","author":"Tallstedt","year":"1993","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071612053021500_R256","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2265.1996.8220832.x","article-title":"Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs. lifetime cigarette consumption.","volume":"45","author":"Pfeilschifter","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R257","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2265.1992.tb01445.x","article-title":"Graves\u2019 ophthalmopathy in relation to cigarette smoking and ethnic origin.","volume":"36","author":"Tellez","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R258","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1530\/eje.0.1380368","article-title":"Effects of smoking on thyroid function.","volume":"138","author":"Utiger","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"2020071612053021500_R259","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1210\/jcem-58-4-615","article-title":"Influence of cigarette smoking on goiter formation, thyroglobulin, and thyroid hormone levels in women.","volume":"58","author":"Borup-Christensen","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R260","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(86)92515-8","article-title":"Homology between thyroglobulin and acetylcholinesterase: an explanation for pathogenesis of Graves\u2019 ophthalmopathy?","volume":"2","author":"Ludgate","year":"1986","journal-title":"Lancet"},{"key":"2020071612053021500_R261","first-page":"96","article-title":"Acetylcholinesterase antibodies and thyroid autoimmunity.","volume":"71","author":"Weetman","year":"1988","journal-title":"Clin Exp Immunol"},{"key":"2020071612053021500_R262","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2265.1994.tb02445.x","article-title":"Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy.","volume":"40","author":"Metcalfe","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612053021500_R263","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/BF01987902","article-title":"Hypoxia\/reoxygenation stimulates endothelial cells to promote interleukin-1 and interleukin-6 production. Effects of free radical scavengers.","volume":"37","author":"Ala","year":"1992","journal-title":"Agents Action"},{"key":"2020071612053021500_R264","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1172\/JCI116122","article-title":"Hypoxia-mediated induction of endothelial cells interleukin-1\u03b1.","volume":"90","author":"Shreeniwas","year":"1992","journal-title":"J Clin Invest"},{"key":"2020071612053021500_R265","first-page":"449","article-title":"Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves\u2019 ophthalmopathy.","volume":"81","author":"Tan","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R266","first-page":"2244","article-title":"Soluble interleukin-1 receptor antagonist serum levels in smokers and nonsmokers with Graves\u2019 ophthalmopathy undergoing orbital radiotherapy.","volume":"82","author":"Hofbauer","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R267","first-page":"1018","article-title":"Detection and modulation of interleukin-1 receptor antagonist messenger ribonucleic acid and immunoreactivity in Graves\u2019 orbital fibroblasts.","volume":"38","author":"Muhlberg","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2020071612053021500_R268","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/archopht.116.8.1106","article-title":"Is Graves ophthalmopathy a preventable disease?","volume":"116","author":"Keltner","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"2020071612053021500_R269","first-page":"10","author":"Houssiau","year":"1995"},{"key":"2020071612053021500_R270","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0002-9343(99)80109-0","article-title":"Biological therapies: a novel approach to the treatment of autoimmune disease.","volume":"99","author":"Fox","year":"1995","journal-title":"Am J Med"},{"key":"2020071612053021500_R271","doi-asserted-by":"crossref","first-page":"231","DOI":"10.7326\/0003-4819-128-3-199802010-00010","article-title":"Rheumatoid arthritis: anticytokine therapies on the horizon.","volume":"128","author":"Koopman","year":"1998","journal-title":"Ann Intern Med"},{"key":"2020071612053021500_R272","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor \u03b1 (cA2) vs. placebo in rheumatoid arthritis.","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"2020071612053021500_R273","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/rheumatology\/34.4.334","article-title":"The therapeutic effects of an engineered human antitumor necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.","volume":"34","author":"Rankin","year":"1995","journal-title":"Br J Rheumatol"},{"key":"2020071612053021500_R274","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/art.1780390212","article-title":"Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis.","volume":"39","author":"Drevlow","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2020071612053021500_R275","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1445-5994.1997.tb00935.x","article-title":"The use of biologics in the treatment of rheumatoid arthritis \u2014 the good news and the bad news.","volume":"27","author":"McQueen","year":"1997","journal-title":"Aust NZ J Med"},{"key":"2020071612053021500_R276","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jcem.83.1.4478","article-title":"Nicotinamide decreases cytokine-induced activation of orbital fibroblasts from patients with thyroid-associated ophthalmopathy.","volume":"83","author":"Hiromatsu","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R277","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1210\/jcem.82.6.9995","article-title":"Beneficial effect of pentoxyfilline on thyroid-associated ophthalmopathy.","volume":"82","author":"Balazs","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612053021500_R278","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1530\/acta.0.1290322","article-title":"Pentoxyfilline inhibits the proliferation and and glycosaminoglycan synthesis of cultured fibroblasts derived from patients with Graves\u2019 ophthalmopathy and pretibial myxoedema.","volume":"129","author":"Chang","year":"1993","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071612053021500_R279","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-2007-978919","article-title":"Inhibitory effect of pentoxyfilline on HLA-DR and glycosaminoglycan synthesis of retrobulbar fibroblasts induced by interleukin-1, tumor necrosis factor\u03b1 and interferon \u03b3.","volume":"30","author":"Balazs","year":"1998","journal-title":"Horm Metab Res"},{"key":"2020071612053021500_R280","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1210\/endo.136.8.7543043","article-title":"Suppression of development of experimental autoimmune thyroiditis by oral administration of thyroglobulin.","volume":"136","author":"Guimaraes","year":"1995","journal-title":"Endocrinology"},{"key":"2020071612053021500_R281","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1089\/thy.1999.9.831","article-title":"The oral administration of human thyroglobulin does not affect the incidence of lymphocytic thyroiditis in the biobreeding Worcester rat.","volume":"9","author":"Colzani","year":"1999","journal-title":"Thyroid"},{"key":"2020071612053021500_R282","author":"Stamato"},{"key":"2020071612053021500_R283","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0161-6420(96)30579-4","article-title":"Long-term follow-up of Graves ophthalmopathy in an incidence cohort.","volume":"103","author":"Bartley","year":"1996","journal-title":"Ophthalmology"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/21\/2\/168\/8859979\/edrv0168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/21\/2\/168\/8859979\/edrv0168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T11:14:39Z","timestamp":1688901279000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/21\/2\/168\/2423888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4,1]]},"references-count":283,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/edrv.21.2.0393","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,4,1]]}}}